Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Chantal Blomme"'
Autor:
Henk-Jan Guchelaar, Ben Van Calster, Vincent Olaf Dezentjé, Ignace Vergote, Robert Paridaens, Johan Van Ginderachter, Willem Lybaert, Sabine Van Huffel, Minne Casteels, Wim Wynendaele, Peter Vuylsteke, Markus Joerger, Didier Verhoeven, Patrick Berteloot, Jan Decloedt, Olivier Brouckaert, Anne-Sophie Dieudonné, Hans Wildiers, An Poppe, Diether Lambrechts, Chantal Blomme, Kathleen Van Asten, Anneleen Lintermans, Lynn Jongen, Patrick Neven
Results of ordinal regression models of the questionnaire items on endoxifen level after multiple imputation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43fa21792371ae5a1e9eef38466b4716
https://doi.org/10.1158/1078-0432.22464206.v1
https://doi.org/10.1158/1078-0432.22464206.v1
Autor:
Henk-Jan Guchelaar, Ben Van Calster, Vincent Olaf Dezentjé, Ignace Vergote, Robert Paridaens, Johan Van Ginderachter, Willem Lybaert, Sabine Van Huffel, Minne Casteels, Wim Wynendaele, Peter Vuylsteke, Markus Joerger, Didier Verhoeven, Patrick Berteloot, Jan Decloedt, Olivier Brouckaert, Anne-Sophie Dieudonné, Hans Wildiers, An Poppe, Diether Lambrechts, Chantal Blomme, Kathleen Van Asten, Anneleen Lintermans, Lynn Jongen, Patrick Neven
Kaplan-Meier curves stratified by endoxifen levels using a quartile split.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11fdb0600a05e7a84478d0598a6582ef
https://doi.org/10.1158/1078-0432.22464215
https://doi.org/10.1158/1078-0432.22464215
Autor:
Henk-Jan Guchelaar, Ben Van Calster, Vincent Olaf Dezentjé, Ignace Vergote, Robert Paridaens, Johan Van Ginderachter, Willem Lybaert, Sabine Van Huffel, Minne Casteels, Wim Wynendaele, Peter Vuylsteke, Markus Joerger, Didier Verhoeven, Patrick Berteloot, Jan Decloedt, Olivier Brouckaert, Anne-Sophie Dieudonné, Hans Wildiers, An Poppe, Diether Lambrechts, Chantal Blomme, Kathleen Van Asten, Anneleen Lintermans, Lynn Jongen, Patrick Neven
List of participating centres and number of patients included.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005fbe1f518021fc5cec158a2b790adf
https://doi.org/10.1158/1078-0432.22464209.v1
https://doi.org/10.1158/1078-0432.22464209.v1
Autor:
Henk-Jan Guchelaar, Ben Van Calster, Vincent Olaf Dezentjé, Ignace Vergote, Robert Paridaens, Johan Van Ginderachter, Willem Lybaert, Sabine Van Huffel, Minne Casteels, Wim Wynendaele, Peter Vuylsteke, Markus Joerger, Didier Verhoeven, Patrick Berteloot, Jan Decloedt, Olivier Brouckaert, Anne-Sophie Dieudonné, Hans Wildiers, An Poppe, Diether Lambrechts, Chantal Blomme, Kathleen Van Asten, Anneleen Lintermans, Lynn Jongen, Patrick Neven
Bland-Altman plot of endoxifen (in µg/l) at 3 months and at 6 months.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5ce7912ef405fe5b225f10a1352ff1
https://doi.org/10.1158/1078-0432.22464218.v1
https://doi.org/10.1158/1078-0432.22464218.v1
Autor:
Henk-Jan Guchelaar, Ben Van Calster, Vincent Olaf Dezentjé, Ignace Vergote, Robert Paridaens, Johan Van Ginderachter, Willem Lybaert, Sabine Van Huffel, Minne Casteels, Wim Wynendaele, Peter Vuylsteke, Markus Joerger, Didier Verhoeven, Patrick Berteloot, Jan Decloedt, Olivier Brouckaert, Anne-Sophie Dieudonné, Hans Wildiers, An Poppe, Diether Lambrechts, Chantal Blomme, Kathleen Van Asten, Anneleen Lintermans, Lynn Jongen, Patrick Neven
Flowchart of patients who were included/excluded from the study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf31fddbfcd8a0db2e9ff07dcd2b1329
https://doi.org/10.1158/1078-0432.22464221.v1
https://doi.org/10.1158/1078-0432.22464221.v1
Autor:
Henk-Jan Guchelaar, Ben Van Calster, Vincent Olaf Dezentjé, Ignace Vergote, Robert Paridaens, Johan Van Ginderachter, Willem Lybaert, Sabine Van Huffel, Minne Casteels, Wim Wynendaele, Peter Vuylsteke, Markus Joerger, Didier Verhoeven, Patrick Berteloot, Jan Decloedt, Olivier Brouckaert, Anne-Sophie Dieudonné, Hans Wildiers, An Poppe, Diether Lambrechts, Chantal Blomme, Kathleen Van Asten, Anneleen Lintermans, Lynn Jongen, Patrick Neven
Quality of Life Questionnaire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f41b5dff874faeab78ff72b99ea8392
https://doi.org/10.1158/1078-0432.22464224
https://doi.org/10.1158/1078-0432.22464224
Autor:
Herman Depypere, G. Vandeputte, Chantal Blomme, A. S Dieudonne, Christel Fontaine, Vincent O. Dezentjé, Patrick Berteloot, J. Decloedt, M-R Christiaens, H. Wildiers, Anneleen Lintermans, Annouschka Laenen, C Vereecke, Markus Joerger, Patrick Neven, D Lambrechts, B. Van Calster, D. Timmerman, A Poppe
Publikováno v:
Cancer Research. 76:P3-07
Background: Tamoxifen is commonly used for the treatment of all stages of estrogen receptor (ER) positive breast cancer (BC), the largest group of BC. In postmenopausal women, known endometrial side-effects are cystic appearance, hyperplasia, polyps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7119437ecaec783dd3a9bda7b721560
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-46
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-46
Autor:
J. Vlasselaer, Eric de Jonge, Johan Van Ginderachter, Ignace Vergote, Gregg Van de Putte, Chantal Blomme, Herman Depypere, Dirk Timmerman, Ben Van Calster, Sabine Van Huffel, Rudy Van den Broecke, G Vlaemynck, Patrick Berteloot, Patrick Neven, Frédéric Amant
Publikováno v:
Menopause (New York, N.Y.), 18(2), 224-229. Lippincott Williams and Wilkins
Objective Before the knowledge that 5 years of adjuvant tamoxifen is less efficacious than 2 to 3 years of tamoxifen followed by 2 to 3 years of anastrozole/exemestane, we designed a multicenter double-blind randomized controlled trial in women takin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5afb7bb2179e42d9916cd75d2091086
https://doi.org/10.1097/gme.0b013e3181eb9f14
https://doi.org/10.1097/gme.0b013e3181eb9f14
Autor:
Henk-Jan Guchelaar, Chantal Blomme, Anneleen Lintermans, Robert Paridaens, J. Decloedt, Peter Vuylsteke, Patrick Berteloot, A Poppe, Diether Lambrechts, Lynn Jongen, Patrick Neven, Didier Verhoeven, Kathleen Van Asten, Markus Joerger, Anne-Sophie Dieudonné, Vincent O. Dezentjé, Ben Van Calster, Ignace Vergote, Hans Wildiers, W. Wynendaele
Publikováno v:
Journal of Clinical Oncology. 34:523-523
523Background: Tamoxifen is commonly used to treat estrogen receptor (ER)-positive breast cancers, though the response to tamoxifen and its adverse event profile have a high degree of inter-individ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c50f2d5a0c56498d2c98641d2c0b0c8f
https://doi.org/10.1200/jco.2016.34.15_suppl.523
https://doi.org/10.1200/jco.2016.34.15_suppl.523
Autor:
Kathleen Van Asten, Hans Wildiers, Dirk Timmerman, Anneleen Lintermans, Diether Lambrechts, Chantal Blomme, Anne-Sophie Dieudonné, Vincent O. Dezentjé, J. Decloedt, Marie-Rose Christiaens, Lynn Jongen, Ben Van Calster, Markus Joerger, Olivier Brouckaert, Didier Verhoeven, Khalil Zaman, Patrick Neven, Patrick Berteloot
Publikováno v:
Cancer Research. 75:OT2-1
Background Tamoxifen is commonly used to treat and prevent hormone receptor positive breast cancers. This drug is metabolized into more active metabolites by liver enzymes such as cytochrome P450 (CYP) enzymes. Endoxifen is considered to be the princ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9b8eb977e0e225c23a929ad5792a79d
https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-05
https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-05